Please Wait.....

Report

Europe Pemphigus Vulgaris Market

Market Report I 2025-06-01 I 350 Pages I Data Bridge Market Research

The Europe pemphigus vulgaris market is expected to reach USD 196.84 million by 2032 from USD 106.15 million in 2024, growing at a CAGR of 8.1% in the forecast period of 2025 to 2032.
Market Segmentation:
Europe Pemphigus Vulgaris Market Segmentation, By Diagnosis and Treatment (Diagnosis and Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy), Countries (Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Netherlands, Belgium, Denmark, Finland, Sweden, Switzerland, Norway, and Rest of Europe) - Industry Trends and Forecast to 2032

Overview of Europe Pemphigus Vulgaris Market Dynamics:

Driver

- Emerging treatment options for pemphigus vulgaris

Restraint
- Stringent regulatory guidelines for pemphigus vulgaris drug approval
Opportunity
- Increasing demand for personalized medicine

Market Players:

The key market players operating in the Europe pemphigus vulgaris market are listed below:

- Sanofi (France)
- GRIFOLS SA (Spain)
- F. Hoffmann-La Roche Ltd (Switzerland)
- GSK plc. (U.K.)
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- Fresenius Kabi AG (Germany)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- OCTAPHARMA AG (Switzerland)
- BioXpress Therapeutics SA (Switzerland)
- Accord Healthcare (U.K.)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Amgen Inc (U.S.)
- Lilly (U.S.)
- Baxter (U.S.)

TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW 40
1.4 LIMITATIONS 41
1.5 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 CURRENCY AND PRICING 47
2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
2.6 MULTIVARIATE MODELLING 51
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.8 DBMR MARKET POSITION GRID 54
2.9 MARKET END USER COVERAGE GRID 55
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 64
4.1 PESTAL ANALYSIS 65
4.2 PORTERS FIVE FORCES ANALYSIS 66
4.3 PATENT ANALYSIS 67
4.3.1 PATIENT FLOW DIAGRAM 68
4.3.2 KEY PRICING STRATEGIES 69
4.3.3 FUTURE THERAPIES 69
4.3.4 KEY PATIENT ENROLLMENT STRATEGIES 70
4.4 EUROPE CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET 72
4.5 SUPPLY CHAIN ECOSYSTEM 78
4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: EUROPE PEMPHIGUS VULGARIS MARKET 80
4.7 EPIDEMIOLOGY: EUROPE PEMPHIGUS VULGARIS MARKET 83
4.7.1 INCIDENCE BY GENDER 83
4.7.2 TREATMENT RATE 83
4.7.3 MORTALITY RATE 83
4.7.4 PATIENT TREATMENT SUCCESS RATES 84
5 EUROPE PEMPHIGUS VULGARIS MARKET: REGULATIONS 85
6 MARKET OVERVIEW 91
6.1 DRIVERS 93
6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 93
6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS 94
6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS 95
6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS 96
6.2 RESTRAINTS 97
6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL 97
6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES 98
6.3 OPPORTUNITIES 99
6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 99
6.3.2 INCREASING HEALTHCARE FACILITIES 100
6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT 101
6.4 CHALLENGES 102
6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS 102
6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES 103
7 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 104
7.1 OVERVIEW 105
7.2 TREATMENT 108
7.3 DIAGNOSIS 110
8 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 111
8.1 OVERVIEW 112
8.2 ADULTS 115
8.3 GERIATRIC 115
8.4 PEDIATRIC 116
9 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 117
9.1 OVERVIEW 118
9.2 HOSPITALS 121
9.3 SPECIALTY CLINICS 121
9.4 RESEARCH INSTITUTES 122
9.5 OTHERS 122
10 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 123
10.1 OVERVIEW 124
10.2 HOSPITALS PHARMACY 127
10.3 RETAIL PHARMACY 127
10.4 ONLINE PHARMACY 128
11 EUROPE PEMPHIGUS VULGARIS MARKET, BY REGION 129
11.1 EUROPE 131
11.1.1 GERMANY 135
11.1.2 U.K. 139
11.1.3 FRANCE 142
11.1.4 ITALY 145
11.1.5 SPAIN 148
11.1.6 SWITZERLAND 151
11.1.7 TURKEY 155
11.1.8 RUSSIA 158
11.1.9 BELGIUM 161
11.1.10 NETHERLANDS 165
11.1.11 DENMARK 169
11.1.12 NORWAY 173
11.1.13 FINLAND 177
11.1.14 POLAND 181
11.1.15 SWEDEN 184
11.1.16 REST OF EUROPE 188
12 EUROPE PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 189
12.1 COMPANY SHARE ANALYSIS: EUROPE 189
13 SWOT ANALYSIS 190
14 COMPANY PROFILE 191
14.1 MERCK AND CO. INC. 191
14.1.1 COMPANY SNAPSHOT 191
14.1.2 REVENUE ANALYSIS 191
14.1.3 COMPANY SHARE ANALYSIS 192
14.1.4 PRODUCT PORTFOLIO 192
14.1.5 RECENT DEVELOPMENTS 193
14.2 SANOFI 194
14.2.1 COMPANY SNAPSHOT 194
14.2.2 REVENUE ANALYSIS 194
14.2.3 COMPANY SHARE ANALYSIS 195
14.2.4 PRODUCT PORTFOLIO 195
14.2.5 RECENT DEVELOPMENT 196
14.3 REGENERON PHARMACEUTICALS INC. 197
14.3.1 COMPANY SNAPSHOT 197
14.3.2 REVENUE ANALYSIS 197
14.3.3 COMPANY SHARE ANALYSIS 198
14.3.4 PRODUCT PORTFOLIO 198
14.3.5 RECENT DEVELOPMENTS 199
14.4 JOHNSON & JOHNSON SERVICES, INC. 200
14.4.1 COMPANY SNAPSHOT 200
14.4.2 REVENUE ANALYSIS 200
14.4.3 COMPANY SHARE ANALYSIS 201
14.4.4 PRODUCT PORTFOLIO 201
14.4.5 RECENT DEVELOPMENT 202
14.5 ASTRAZENECA 203
14.5.1 COMPANY SNAPSHOT 203
14.5.2 REVENUE ANALYSIS 203
14.5.3 COMPANY SHARE ANALYSIS 204
14.5.4 PRODUCT PORTFOLIO 204
14.5.5 RECENT DEVELOPMENT 205
14.6 ABBVIE INC. 206
14.6.1 COMPANY SNAPSHOT 206
14.6.2 REVENUE ANALYSIS 206
14.6.3 PRODUCT PORTFOLIO 207
14.6.4 RECENT DEVELOPMENT 208
14.7 ACCORD HEALTHCARE 210
14.7.1 COMPANY SNAPSHOT 210
14.7.2 PRODUCT PORTFOLIO 210
14.7.3 RECENT DEVELOPMENT 210
14.8 AMGEN INC. 211
14.8.1 COMPANY SNAPSHOT 211
14.8.2 REVENUE ANALYSIS 211
14.8.3 PRODUCT PORTFOLIO 212
14.8.4 RECENT DEVELOPMENT 213
14.9 ARTIVA BIOTHERAPEUTICS, INC. 214
14.9.1 COMPANY SNAPSHOT 214
14.9.2 REVENUE ANALYSIS 214
14.9.3 PRODUCT PIPELINE PORTFOLIO 215
14.9.4 RECENT DEVELOPMENT 215
14.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 216
14.10.1 COMPANY SNAPSHOT 216
14.10.2 PRODUCT PORTFOLIO 216
14.10.3 RECENT DEVELOPMENT 216
14.11 BAXTER 217
14.11.1 COMPANY SNAPSHOT 217
14.11.2 REVENUE ANALYSIS 217
14.11.3 PRODUCT PORTFOLIO 218
14.11.4 RECENT DEVELOPMENT 218
14.12 BIOXPRESS THERAPEUTICS SA 219
14.12.1 COMPANY SNAPSHOT 219
14.12.2 PRODUCT PORTFOLIO 219
14.12.3 RECENT DEVELOPMENT 219
14.13 CABALETTA BIO INC. 220
14.13.1 COMPANY SNAPSHOT 220
14.13.2 REVENUE ANALYSIS 220
14.13.3 PRODUCT PORTFOLIO 220
14.13.4 RECENT DEVELOPMENT 221
14.14 CIPLA HEALTH LTD 222
14.14.1 COMPANY SNAPSHOT 222
14.14.2 PRODUCT PORTFOLIO 222
14.14.3 RECENT DEVELOPMENTS 222
14.15 CELLTRION 223
14.15.1 COMPANY SNAPSHOT 223
14.15.2 REVENUE ANALYSIS 223
14.15.3 PRODUCT PORTFOLIO 224
14.15.4 RECENT DEVELOPMENTS 225
14.16 CSL 226
14.16.1 COMPANY SNAPSHOT 226
14.16.2 REVENUE ANALYSIS 226
14.16.3 PRODUCT PORTFOLIO 227
14.16.4 RECENT DEVELOPMENT 227
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD. 228
14.17.1 COMPANY SNAPSHOT 228
14.17.2 REVENUE ANALYSIS 228
14.17.3 PRODUCT PORTFOLIO 229
14.17.4 RECENT DEVELOPMENT 229
14.18 F. HOFFMANN- LA ROCHE LTD. 230
14.18.1 COMPANY SNAPSHOT 230
14.18.2 REVENUE ANALYSIS 230
14.18.3 PRODUCT PORTFOLIO 231
14.18.4 RECENT DEVELOPMENT/NEWS 231
14.19 FRESENIUS KABI AG 233
14.19.1 COMPANY SNAPSHOT 233
14.19.2 REVENUE ANALYSIS 233
14.19.3 PRODUCT PORTFOLIO 234
14.19.4 RECENT DEVELOPMENT 234
14.20 GSK PLC 236
14.20.1 COMPANY SNAPSHOT 236
14.20.2 REVENUE ANALYSIS 236
14.20.3 PRODUCT PORTFOLIO 237
14.20.4 RECENT DEVELOPMENT 237
14.21 GRIFOLS, S.A. 239
14.21.1 COMPANY SNAPSHOT 239
14.21.2 REVENUE ANALYSIS 239
14.21.3 PRODUCT PORTFOLIO 240
14.21.4 RECENT DEVELOPMENT 240
14.22 INCYTE 241
14.22.1 COMPANY SNAPSHOT 241
14.22.2 REVENUE ANALYSIS 241
14.22.3 PRODUCT PORTFOLIO 242
14.22.4 RECENT DEVELOPMENT 242
14.23 NOVARTIS AG 243
14.23.1 COMPANY SNAPSHOT 243
14.23.2 REVENUE ANALYSIS 243
14.23.3 PRODUCT PORTFOLIO 244
14.23.4 RECENT DEVELOPMENT 244
14.24 LILLY 245
14.24.1 COMPANY SNAPSHOT 245
14.24.2 REVENUE ANALYSIS 245
14.24.3 PRODUCT PORTFOLIO 246
14.24.4 RECENT DEVELOPMENT 246
14.25 OCTAPHARMA AG 247
14.25.1 COMPANY SNAPSHOT 247
14.25.2 REVENUE ANALYSIS 247
14.25.3 PRODUCT PORTFOLIO 248
14.25.4 RECENT DEVELOPMENT/NEWS 248
14.26 PFIZER INC. 249
14.26.1 COMPANY SNAPSHOT 249
14.26.2 REVENUE ANALYSIS 249
14.26.3 PRODUCT PORTFOLIO 250
14.26.4 RECENT DEVELOPMENT 250
14.27 RAKSHIT DRUGS PVT. LTD 251
14.27.1 COMPANY SNAPSHOT 251
14.27.2 PRODUCT PORTFOLIO 251
14.27.3 RECENT DEVELOPMENT 252
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD. 253
14.28.1 COMPANY SNAPSHOT 253
14.28.2 REVENUE ANALYSIS 253
14.28.3 PRODUCT PORTFOLIO 254
14.28.4 RECENT DEVELOPMENT 254
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD 255
14.29.1 COMPANY SNAPSHOT 255
14.29.2 REVENUE ANALYSIS 255
14.29.3 PRODUCT PORTFOLIO 256
14.29.4 RECENT DEVELOPMENT 256
14.30 ZYDUS GROUP 258
14.30.1 COMPANY SNAPSHOT 258
14.30.2 REVENUE ANALYSIS 258
14.30.3 PRODUCT PORTFOLIO 259
14.30.4 RECENT DEVELOPMENT 260
15 QUESTIONNAIRE 261
16 RELATED REPORTS 264
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.